The study by Loaiza et al was well-designed and thorough, but differs from the current investigation in two important experimental variables: 1) the strategy used to generate Stap1 KO mice, using clustered regularly interspaced short palindromic repeats/clustered regularly interspaced short palindromic repeat-associated 9 (CRISPR/Cas9) technology vs targeted homologous recombination of embryonic stem cells and 2) the much shorter time period for hyperlipidemia induction in global and tissue-specific KO mice (4 weeks vs 12 weeks). This evidence concerns the gene STAP1 and hyperlipidemia.